138 related articles for article (PubMed ID: 29909410)
1. What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease?
Saleem MA
Nephron; 2018; 139(4):334-341. PubMed ID: 29909410
[TBL] [Abstract][Full Text] [Related]
2. suPAR and chronic kidney disease-a podocyte story.
Zeier M; Reiser J
Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
Hahm E; Wei C; Fernandez I; Li J; Tardi NJ; Tracy M; Wadhwani S; Cao Y; Peev V; Zloza A; Lusciks J; Hayek SS; O'Connor C; Bitzer M; Gupta V; Sever S; Sykes DB; Scadden DT; Reiser J
Nat Med; 2017 Jan; 23(1):100-106. PubMed ID: 27941791
[TBL] [Abstract][Full Text] [Related]
4. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
Weidemann DK; Abraham AG; Roem JL; Furth SL; Warady BA
Am J Kidney Dis; 2020 Aug; 76(2):194-202. PubMed ID: 31987488
[TBL] [Abstract][Full Text] [Related]
5. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
[TBL] [Abstract][Full Text] [Related]
6. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
[TBL] [Abstract][Full Text] [Related]
7. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
Bock ME; Price HE; Gallon L; Langman CB
Clin J Am Soc Nephrol; 2013 Aug; 8(8):1304-11. PubMed ID: 23620441
[TBL] [Abstract][Full Text] [Related]
9. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin.
Hladunewich MA; Cattran D; Sethi SM; Hayek SS; Li J; Wei C; Mullin SI; Reich HN; Reiser J; Fervenza FC
Kidney Int Rep; 2022 Jan; 7(1):68-77. PubMed ID: 35005315
[TBL] [Abstract][Full Text] [Related]
11. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
12. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
[TBL] [Abstract][Full Text] [Related]
14. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
[TBL] [Abstract][Full Text] [Related]
15. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.
Cathelin D; Placier S; Ploug M; Verpont MC; Vandermeersch S; Luque Y; Hertig A; Rondeau E; Mesnard L
J Am Soc Nephrol; 2014 Aug; 25(8):1662-8. PubMed ID: 24790179
[TBL] [Abstract][Full Text] [Related]
16. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
[TBL] [Abstract][Full Text] [Related]
17. Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
Outinen TK; Mäkelä S; Huttunen R; Mäenpää N; Libraty D; Vaheri A; Mustonen J; Aittoniemi J
J Intern Med; 2014 Oct; 276(4):387-95. PubMed ID: 24717117
[TBL] [Abstract][Full Text] [Related]
18. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
[TBL] [Abstract][Full Text] [Related]
19. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
Franco Palacios CR; Lieske JC; Wadei HM; Rule AD; Fervenza FC; Voskoboev N; Garovic VD; Zand L; Stegall MD; Cosio FG; Amer H
Transplantation; 2013 Aug; 96(4):394-9. PubMed ID: 23736353
[TBL] [Abstract][Full Text] [Related]
20. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
Jin J; Li YW; He Q
Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
